August 9, 2023 News by Lindsey Shapiro, PhD Ibudilast treatment found to protect tissue integrity in brain in MS Treatment with ibudilast ā an anti-inflammatory being developed to treat people with progressive forms ofĀ multiple sclerosis (MS) ā significantly preserved tissue integrity in a brain region called the thalamus in patients in a clinical trial, according to new analyses from SPRINT-MS. While the therapy appeared to exert these…
January 26, 2021 News by Aisha I Abdullah PhD PPMS Patients ‘Drove’ Slowing in Brain Atrophy Seen With Ibudilast, Trial Analysis Finds People with primary progressive MS (PPMS) appeared to show a much stronger response and to be the” driving” force behind a slowing in brain atrophy seen withĀ ibudilastĀ treatment in the SPRINTāMS trial, a post-hoc study analysis reports. The treatment response observed in brain atrophy was more evident…
August 30, 2019 News by Jose Marques Lopes, PhD Higher Vitamin D Levels May Promote ‘Myelin Integrity’ in Progressive MS, Study Suggests Higher levels of vitamin D in the blood may help to protect the myelin sheath, slowing damage to nerve cells in people withĀ progressive forms of multiple sclerosis (MS), a brain imaging study reports. The study, āVitamin D and MRI measures in progressive multiple sclerosis,ā was published in the…
April 4, 2019 News by Jose Marques Lopes, PhD #AANAM – Ibudilast Slows Brain Atrophy in PPMS But Not SPMS Patients, Phase 2b Trial Shows Treatment with oral ibudilast slowsĀ brain shrinkage in patients with primary progressive multiple sclerosis (PPMS), but not in those with secondary progressive MS (SPMS), according to results of a Phase 2b clinical trial. According to the findings, this could be partially due to faster disease progression in untreated…
September 18, 2018 News by Jose Marques Lopes, PhD Ibudilast Slows Brain Shrinkage 48% in Progressive MS Patients in Phase 2 Trial; Lead Researcher Says Finding is ‘Remarkable’ Progressive multiple sclerosis patients ā with primary or secondary progressive disease ā treated with high doses of oralĀ ibudilastĀ in a Phase 2 clinical trial showed a 48 percent slowing in the progression of brain atrophy, or shrinkage, relative to those given a placebo, study data show. What this…
April 19, 2018 News by Patricia Inacio, PhD #AAN2018 ā Investigational Therapy Ibudilast Slows Brain Atrophy in Phase 2 Trial for Progressive MS Investigational therapyĀ ibudilastĀ leads to a significant reduction of brain atrophy, supporting its potential to effectively treat progressive multiple sclerosis (MS), new data from a Phase 2 clinical trial show. These results will be shared at the upcoming 2018 Annual MeetingĀ of theĀ American…
February 2, 2018 News by Patricia Inacio, PhD #ACTRIMS2018 ā MediciNova Presents Positive Results from SPRINT-MS Trial Evaluating Ibudilast in Progressive MS Top-line results from a clinical trial evaluating the investigational oral therapy ibudilast for progressive multiple sclerosis (MS) show that the therapy led to a significant reduction of brain atrophy in patients when compared to controls. Robert Naismith, MD, one of the study’s principal researchers fromĀ Washington University in St. Louis,…
October 30, 2017 News by Patricia Inacio, PhD #MSParis2017 – Ibudilast Slows Loss of Brain Tissue in MS Patients, Phase 2 Trial Shows The Japanese companyĀ MediciNova‘s anti-inflammatory agentĀ ibudilast slows multiple sclerosis patients’ brain shrinkage and their loss of the protective myelin coating around nerve cells, a Phase 2 clinical trial shows. Robert J. Fox of Ohio’s Cleveland Clinic Neurological InstituteĀ presented the results at theĀ 7th Joint ECTRIMS-ACTRIMS MeetingĀ in Paris, Oct. 25-28.
May 8, 2015 News by Patricia Silva, PhD MediciNova Completes Enrollment for Phase 2b Study of Experimental Progressive Multiple Sclerosis Treatment MediciNova, Inc., a publicly-traded biopharmaceutical company developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical needs, recently announced that the National Institute of Neurological Disorders and Stroke (NINDS) notified the company of full enrollment of theirĀ ongoing clinical study evaluating ibudilastĀ (MN-166) for the treatment of progressive…